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Brain protection of the newborn remains a challenging priority and represents a totally unmet medical need. Pharmacological
inhibition of caspases appears as a promising strategy for neuroprotection. In a translational perspective, we have developed a
pentapeptide-based group II caspase inhibitor, TRP601/ORPHA133563, which reaches the brain, and inhibits caspases
activation, mitochondrial release of cytochrome c, and apoptosis in vivo. Single administration of TRP601 protects newborn
rodent brain against excitotoxicity, hypoxia–ischemia, and perinatal arterial stroke with a 6-h therapeutic time window, and has
no adverse effects on physiological parameters. Safety pharmacology investigations, and toxicology studies in rodent and
canine neonates, suggest that TRP601 is a lead compound for further drug development to treat ischemic brain damage in
human newborns.
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Worldwide estimations indicate more than 2 million non-
infectious neonatal deaths per year.
1 Neonatal ischemic brain
injuries, such as stroke (focal cerebral ischemia involving middle
cerebral artery occlusion (MCAO)) or hypoxia–ischemia (HI)
(involving systemic asphyxia), are major and untreated causes
of newborn morbidity and mortality.
2,3 O ft h ei n f a n t sw h os u r v i v e
the ﬁrst few hours after intrapartum-related neonatal deaths
(previously called ‘birth asphyxia’), as many as an annual
1 million may develop cerebral palsy, learning difﬁculties or other
disabilities.
4 Recent clinical trials show that therapeutic inter-
vention by brain cooling beginning up to 6h after perinatal
asphyxiareducescerebralinjuryandimprovesoutcomesinterm
infants.
5 Although these studies provide proof of concept that in
this context cell death is both delayed and preventable, the
protection is limited and there is still no treatment available for
perinatal stroke or brain injury occurring in preterm infants.
6
Ischemic brain injury in the developing brain involves
several factors such as excitotoxicity, oxidative stress, and
inﬂammation, which accelerate cell death through either
apoptosis or necrosis, depending on the region of the brain
affectedandontheseverityoftheinsult.
7,8Accumulating data
suggest that apoptotic mechanisms have a more prominent
role in the evolution of ischemic brain injury in neonatal
rodents
9–11 and humans
12 than in adult brain ischemia,
13,14
and that apoptosis involves the mitochondrial release of
cytochrome c
11 and apoptosis-inducing factor (AIF),
11,15,16
which activate caspase-dependent
10,16 and -independent
execution pathways,
13,16 respectively.
Caspases are a class of cysteine endoproteases that have
strict speciﬁcity for an aspartic residue at the S1 subsite.
17,18
Some caspases are important mediators of inﬂammation and
others are involved in the apoptosis of mammalian cells,
where they participate in signaling and effector pathways.
19
On the basis of the optimal four-amino-acid sequence to the
left of the cleavage site, caspases may be classiﬁed into three
groups: group I contains caspase-1, -4, and -5 (optimal
tetrapeptide:WEHD),groupIIcontainscaspase-2(Casp2),-3
(Casp3), and -7 (Casp7) (optimal tetrapeptide: D[E/A]XD),
and group III contains caspase-6, -8 (Casp8), -9 (Casp9), and
-10 (optimal tetrapeptide: [V/L]EXD).
20–22
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www.nature.com/cddisBoth pancaspase inhibition and Casp3-selective inhibition
have been reported to be neuroprotective in various rodent
models of neonatal brain injury,
13,23,24 opening the possibility
for pharmacological intervention.
6 However, lack of protection
with caspase inhibitors was also reported,
25,26 possibly
reﬂecting differences between experimental models or set-
tings (e.g., the age of animals
26), speciﬁc in vivo properties of
the used inhibitors (e.g., brain penetration
27), and/or a shift to
caspase-independent cell death pathways (e.g., AIF, auto-
phagic death, necroptosis).
Theroleofindividualcaspasesinthedevelopingbrainisnot
fully understood. Genetic analysis using constitutive deﬁ-
ciency revealed that Casp3 and Casp9 execute programmed
(physiological) cell death in the central nervous system,
28,29
whereasCasp2doesnot.
30AggravationofHI-inducedlesions
was reported in Casp3-null mice.
31 In contrast, genetic
inhibition of Casp2 is neuroprotective in newborn mice
exposed to HI or excitotoxic challenges.
32
In a translational attempt to generate an efﬁcient and safe
Casp2/group-IIcaspaseinhibitor,wehavedevelopedapotent
pentapeptide-based irreversible caspase inhibitor. We report
here the preclinical evaluation of this compound and present
data supporting a potent neuroprotective role against perina-
tal ischemic brain damage in a variety of in vivo models,
potentially opening an avenue for treatment.
Results
Design of a caspase inhibitor adapted for neuroprotection
in neonates. We previously showed that the pancaspase
inhibitor quinolyl-carbonyl-Val-Asp-diﬂuorophenoxymethyl-
ketone (Q-VD-OPh) has enhanced in vitro and in vivo
pharmacological properties,
33 together with potent neuro-
protective effects in neonatal brain injury experimental
models.
10,16,34 We reasoned that an in vivo efﬁcient group
II-selective caspase inhibitor might combine an amino-terminal
quinolyl-carbonyl and a C-terminal ﬂuorophenoxymethyl
ketone warhead (CH2OC6H3-F2) with the Casp2-preferred
pentapeptide backbone VDVAD,
20,33,35,36 a sequence that is
also efﬁcient as a substrate for Casp3,
37 but is a weaker
substrate for group-I and -III caspases (data not shown and
McStay et al.
37). Using the reported Casp2 crystallographic
data,
38 we modeled pentapeptide structures within the
Casp2 active site (Figure 1a and Supplementary Figure
S1), and chose to add methyl ester group to the lateral chain
of each Asp residues to enhance lipophilicity (a well-known
approach to promote blood–brain barrier penetration) and
delay degradation by proteases in vivo. The resulting
substituted pentapeptide quinolin-2-carbonyl-VD(OMe)VAD
(OMe)-CH2-O(2,6F2)Ph (referred thereafter as TRP601) was
selected (Figure 1b). TRP601 is an irreversible caspase
inhibitor that, similar to other VDVAD-based inhibitors,
20,21,37
is a potent inhibitor of group II caspases. Indeed, in vitro
kinetic analysis showed that TRP601 potently inhibits Casp3
(IC50/Casp3/TRP601¼47.3±11.2nM; k3/Ki¼36025/M/s; n¼3)
and also inhibits recombinant Casp2 (IC50/Casp2/TRP601¼
479.8±79.3nM; k3/Ki¼1243/M/s; n¼3) (Figures 1c and d).
According to its irreversible nature, TRP601 showed
a fourfold IC50 reduction if preincubated 45min with
Casp2 before substrate addition (IC50/rCasp2/TRP601/45min¼
127±25nM; n¼3).
As expected, TRP601 had no substantial activity outside
the caspase family, as found in a binding screen of 110
different receptors, transporters and ion channels, and 56
enzyme activity assays, including calpains, various cathe-
psins (B, H, G, L), granzyme B, and several glutamatergic
sites such as N-methyl-D-aspartatic acid and a-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (Table 1). When
used in cell culture assays like serum-deprived primary
embryonic cortical neurons,
39 TRP601 prevented caspase
activation and cell death (Figure 1e). Following intravenous
(i.v.) administration in adult rats, TRP601 quickly entered the
brain (Figure 1f; Tmax¼25min in the brain; Cmax¼120ng/ml
in the brain, 1mg/kg, i.v. bolus dose). Interestingly, an active
metabolite D2Me-TRP601 (TRP601 devoid of methyl ester
Figure 1 Design and pharmacological evaluation of TRP601. (a) Substrate binding region of caspase-2 (Casp2) in complex with TRP601. The quinolin-2-carbonyl-Val-
Asp(OMe)-Val-Ala-Asp(OMe)-CH2- moiety is shown in sticks representation with the atoms represented as follows: gray¼carbon; white¼hydrogen; blue¼nitrogen; and
red¼oxygen. The S–C covalent bond between the Cys-155 residue and the C terminus CH2 of TRP601 is represented in yellow. The electric interactions (hydrogen bonds
andsaltsbridges)arerepresentedbythedashed,greenlines.Theenzymeresiduesthatinteractwiththeinhibitorareshownbythewireframerepresentation.Rightpanel:the
table shows the minimal energy (kcal/mol, Emin) of the Casp2–TRP601 complex resulting from electric or Coulombic component (Ec) together with repulsion–attraction
component (Evw). The interaction energy of the Casp2–TRP601 complex is  147.28kcal/mol. Owing to the C–S covalent bond, the Asp residue in P1 contributes to about
30% of the interaction energy. The Asp in P4 and the Val in P5 have important non-covalent contributions to stabilization of the complex, 21% and 17%, respectively. Each of
the other two residues (Ala in P2 and Val in P3) contributes to about 12% of the interaction energy. (b) Structure of TRP601. (c) Representative dose–response curve of
human recombinant Casp2 and Casp3 inhibition by TRP601. Initial velocities were determined from standard colorimetric microplate assays. (d) Kinetic off rate (k3/Ki)
parameters of irreversible caspase inhibitors on Casp2 and Casp3. (e) TRP601 inhibits neuronal caspase activities and prevents serum deprivation (SD)-induced cell death.
High-densityE14corticalneuronculturesweresubjectedto24hSDinthepresenceorabsenceof50mMTRP601.Histogramsindicatethemeans(±S.D.)of15independent
experiments. (f) Representative pharmacokinetic of TRP601 after intravenous (i.v.) administration in adult rats, through liquid chromatography-mass spectrometry (LC-MS/
MS) detection in the plasma and brain homogenates. Note that following intraperitoneal (i.p.) administration of the same dose, TRP601 was detected in the brain at 0.25h
(brainCmax¼25ng/ml)andtheCmax(20ng/ml)wasobtainedintheplasmaaccordingtoaplateaubetween0.5and2h.(g–j)TRP601reducesexcitotoxiclesionsinneonates.
The5-day-oldmiceweresubjectedtointracerebralibotenateinjectionandkilledatdifferenttimepoints(g¼5days;handi¼24h;j¼8h)followingtheexcitotoxicchallenge
to determine the impact of TRP601, TRP801, and TRP901 (1mg/kg; i.p.) on lesion severity (g), microgliosis (h), astrogliosis (i), and group II caspases activity (j). Histograms
show mean lesion volume (g; ’, vehicle, n¼16; TRP601, n¼16; TRP801, n¼7; TRP901, n¼8), cell density (h and i; n¼10 per group), or VDVADase activity (j; n¼5
per group)±S.E.M. Asterisks indicate differences from control (’)( * Po0.05, **Po0.01, ***Po0.001 in Kruskal–Wallis post hoc Dunn’s for g, Mann–Whitney for h–j).
(k)TRP601doesnotenhanceprotectionconferredbyshortinterfering RNA(siRNA)-mediatedgeneticinhibitionof Casp2.The5-day-oldmiceweresubjected tointracerebral
injection (as in c) of either an siRNA against Casp2 (si2-a) or a control siRNA (si2Co), as indicated. After 24h, ibotenate was administered (intracerebroventrally (i.c.v.)),
followed immediately by vehicle (&, n¼20; ’, n¼20) or TRP601 (’; n¼24) administration (i.p.). See Supplementary Table 1 for exact values and detailed statistical
analysis
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Cell Death and Diseasegroups on Asp lateral chains) was progressively generated in
the blood. We have re-synthesized this metabolite and found
that it strongly inhibits Casp3 (IC50/Casp3/D2Me-TRP601 against
recombinant Casp3 (rCasp3)¼0.42±0.16nM; k3/Ki¼
34782163/M/s) and Casp2 (IC50/Casp2/D2Me-TRP601 against
rCasp2¼7.4±3.1nM; k3/Ki¼182801/M/s; n¼3) in vitro.
Table 1 Comprehensive in vitro pharmacology proﬁle of TRP601
Non-peptide receptors Peptide receptors Nuclear receptors
Adenosine Angiotensin-II Glucocorticoid
Adrenergic Bombesin Estrogen alpha
Cannabinoid Calcitonin gene-related peptide Androgen
Dopamine Chemokine
GABA Cholecystokinin Ion channels
Glutamate Complement 5a Ca
2+ channels
Glycine Endothelin K
+ channels
Histamine Galanin Na
+ channel
Imidazole Glucagon
Leukotriene Growth hormone secretagogue Enzymes
Melatonin Melanin-concentrating hormone Kinases
Muscarinic Motilin Phosphatases
Nicotinic Neurokinin Serine proteases
Purinergic Neuropeptide Y Cysteine proteases
Serotonin Neurotensin Aspartate proteases
Sigma Opioid and opioid-like Arachidonic acid metabolism
Somatostatin Prostaglandin metabolism
Amine transporters Thyroid hormone Monoamine synthesis and metabolism
Choline Urotensin-II Neurotransmitter synthesis and metab.
Dopamine Vasoactive intestinal peptide Nitric oxide synthesis
GABA Rolipram Second messenger systems
Norepinephrine Vasopressin ATPases
Seretonin Lipid synthesis
Metalloproteases
Miscellaneous enzymes
TRP601 (10mM) did not signiﬁcantly modify the activity of 56 enzymes and did not impair or increase the binding of speciﬁc ligands to their receptors (110 receptors,
channels, or transporters tested). Synthetic list of enzymes, peptide and non-peptide receptors, nuclear receptors, ion channels, or amine transporters, challenged
with TRP601 (see details in Supplementary Table S3)
Figure 2 TRP601 has neuroprotective effects in a perinatal stroke model. The 7-day-old rats underwent electrocoagulation of the left middle cerebral artery and transient
homolateral common carotid artery occlusion for 50min, followed by 48h of recovery. (a) Pre-treatment with TRP601 confers strong cerebroprotection. Vehicle (’; n¼15),
100mg TRP601 (&; n¼24) or 100mg TRP901 (’; n¼9) was injected intraperitoneally (i.p.) before ischemia. Histograms represent mean±S.E.M. Kruskal–Wallis
(P¼0.0004), post hoc Dunn’s (Po0.001 for TRP601 versus vehicle). (b) Dose–response of TRP601 administered 1h after MCAO onset (n¼103, Po0.002 Kruskal–
Wallis). Histograms represent mean±S.E.M. Asterisks indicate the level of signiﬁcance in Dunn’s post hoc.( c) Representative cresyl violet-stained coronal sections from
vehicle-treated and TRP601-treated (1mg/kg i.p.; 1h post-ischemia) animals at 48h post-reperfusion at the level of dorsal hippocampus and anterior commissure. Dotted
lines indicate infarct area. Scale bar¼500mm. (d) Time window for treatment with TRP601 (n¼274, Po0.0001 Kruskal–Wallis). Individual percentage infarct volumes at
48h post-ischemiaare shown invehicle- (n¼43) or TRP601-treated rats (1mg/kg; i.p.) at 1h (n¼51, ***), 2h (n¼45, ***), 3h (n¼40, ***), 4h (n¼48, *), and 6h (n¼47, *)
post-occlusion(asterisksindicatethelevelofsigniﬁcanceinDunn’sposthoc).Temperatureandbodyweightweresystematicallymonitoredinischemicanimals(treatedornot
with TRP601) and were found unchanged during ischemia, at reperfusion, and up to 48h post-ischemia. (e and f) TRP601 effects after intravenous injection. TRP601 was
administered intrajugularly 1h after the ischemic onset (n¼15). (e) Representative micrographs of entire pup brains at 48h post-stroke. Arrows indicate electrocoagulation
points.Upper micrograph showsrepresentativelesionat 48h with visibleischemic territory.Lower micrographis representative for low lesionalscore found in 33%of animals
injectedwith0.1mg/kgTRP601.(f)Raustro-caudal proﬁles(coronalsectionsofipsilateralhemisphere)afterintravenous(i.v.)administrationof TRP601(1hafterischemia)at
0.1mg/kg (n¼15) or 1mg/kg (n¼16). (g and h) TRP601 has long-term protective effects. Vehicle or 0.1mg/kg TRP601 was i.p. injected 1h after the ischemic onset. After
21 days of recovery, animals were killed. (g) Cresyl violet-stained coronal sections showing brain injury in a representative animal for each treatment (upper: bregma 0.7;
lower:  3.3mm). Note that TRP601 reduces the cortical cavity and tissue loss in external and internal capsule (ec, ic), caudate putamen (CPu), and amygdaloid nucleus
(bregma  3.6,  4mm; data not shown). (h) Quantiﬁcation of the cavity volume (% cavitation) and hemispheric tissue loss (100 % ipsi/contra) in the presence (n¼12) or
absence(n¼6) of TRP601. Data are mean±S.E.M. (bars) values. *P¼0.0017;
#P¼0.0192 (Mann–Whitney). (i and j) In vivo and ex vivo cell death, at 48h post-stroke, in
the ipsilateral cortex of vehicle- and TRP601-treated ischemic animals. Propidium iodide was injected intrajugularly (10mg/kg) into rat pups before ischemia and coronal
sections were analyzed by ﬂuorescence microscopy (i, representative micrograph; j, left histograms). Alternatively, coronal sections were subjected to in situ 30-OH end DNA
labeling (terminal deoxynucleotidyltransferase dUTP nick-end labeling , TUNEL),counterstained with Hoechst33342, and analyzedby ﬂuorescencemicroscopy (j). Data are
mean±S.E.M. (bars) values (n¼5). **P¼0.0079 (Mann–Whitney). The arrows point to apoptotic nuclei. Scale bar¼100mm. (k) Representative western blot analysis of
caspase-2 (Casp2) processing at 24h post-ischemia in the presence or absence of TRP601 or TRP901 injected (1mg/kg, i.p.) at reperfusion. Ipsilateral penumbra zone (IL)
and contralateral counterpart (CL) of hemispheres were dissected and homogenized before biochemical analysis. Co., control brains (without ischemia). (l) Detection of
caspase-likeactivitiesat24hpost-strokeinipsilateralpenumbrazones.HistogramsshowmeansofVDVADase,DEVDase,andLEHDaseactivitiesofanimalsi.p.-treated(’,
n¼5) or not (&, n¼5) with TRP601 or TRP901. Note that kinetic analysis showed that the earliest and quantitatively major detected caspase-like activity is a VDVADase
activity that reached 14pmol/min/mg at t¼5h post-ischemia, whereas neither DEVDase nor LEHDase activities were detected (Supplementary Figure S5). (m) TRP601
preventscytochromecreleaseinvivo.Arepresentativewesternblotanalysisisshown.MF:mitochondrialfraction;CF:cytosolicfraction(CF).(n)Electronmicroscopyanalysis
of themitochondria isolatedfromischemicbrains.The mitochondria isolatedfromvehicle-treated ipsilateral(IL), contralateral (CL) hemispheres, or TRP601-treated ipsilateral
(ILþTRP601) hemispheres are shown. Each panel show an example of the dominant phenotype (460%) of the isolated mitochondria population
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Cell Death and DiseaseTRP601 is neuroprotective in neonatal excitotoxic brain
injury. We next evaluated the effect of TRP601 after
excitotoxic neonatal brain injury. In 5-day-old mice
intracerebrally injected with ibotenate, a single
administration of TRP601 (intraperitoneal (i.p.); 1mg/kg)
signiﬁcantly reduced lesion volumes of cortical
(40.96±0.02%; Po0.001 Kruskal–Wallis post hoc
Dunn’s) (V¼0.23±0.07mm
3, n¼16 versus controls
V¼0.37±0.06mm
3, n¼16) and white matter (48.87±0.01%
reduction; Po0.01) (V¼0.11±0.03mm
3, n¼16 versus
controls V¼0.18±0.08mm
3, n¼16) regions (Figure 1g). In
contrast, TRP901 (a DEVD-based preferential Casp3/Casp7
inhibitor) and TRP801 (a preferential Casp8 inhibitor
40),
both designed with the same chemistry as TRP601
(Supplementary Figure S2), did not confer brain protection
against ibotenate challenge (Figure 1g). In these
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Cell Death and Diseaseexperimental conditions, TRP601 also reduced macrophage
activation (43.51±4.16% reduction; Po0.0001 Mann–
Whitney) and astrogliosis (37.69±3.15% reduction;
Po0.0001 Mann–Whitney) as demonstrated by histological
evaluation of lectine- (Figure 1h) and glial ﬁbrillary acidic
protein -positive (Figure 1i) cell densities, respectively. In
addition, TRP601 strongly reduced the VDVADase-speciﬁc
activity (73% reduction; P¼0.0079 Mann–Whitney) when
studied 8h after ibotenate treatment (Figure 1j).
Having found recently that genetic inhibition of caspase-2
(Casp2) protects newborn mice from ischemic brain injury,
32
we further investigated the protective effect of TRP601 during
Casp2 silencing. When TRP601 was administered in mice
neonates treated with Casp2-speciﬁc siRNA, no signiﬁcant
additional protection was found against ibotenate, neither in
the white matter nor in the cortical plate (Figure 1k and
Supplementary Table S1). This suggests that, at least in this
experimental setting, TRP601-mediated neuroprotection is
Casp2 dependent.
TRP601 is neuroprotective in neonatal rats after
ischemic stroke. We then investigated whether TRP601
might be operative in perinatal arterial stroke. The 7-day-old
rat pups were subjected to a permanent occlusion of the
MCAO and subsequent transient unilateral carotid ligation,
41
a model of neonatal ischemia with reperfusion that induces
ipsilateral cortical injury associated with initiator and effector
caspase processing,
42 extensive neuronal loss, inﬂammatory
responses, nitric oxide production and the evolution of a
cortical cavitary infarct.
41
AsingledoseofTRP601(5mg/kg;i.p.)administeredbefore
occlusion induces a highly signiﬁcant reduction (59%) of
infarction (8.83±1.8%; n¼24) compared with the control
(21.67±1.65%; n¼15) (Figure 2a). In contrast, the Casp3/
Casp7 inhibitor TRP901 does not confer signiﬁcant protection
(22.2±5.67%; n¼9). TRP601 also produces signiﬁcant
reductions in cortical infarction when administered i.p. 1h
aftertheischemiconset(i.e.,atreperfusion)atdosesbetween
1mg/kg and 10mg/kg (n¼103; Po0.002 Kruskal–Wallis),
with an optimal dose of 1mg/kg (% infarction: 9.73±1.9%;
n¼18, Po0.001 post hoc Dunn’s; Figures 2b and c).
TodeterminethetherapeutictimewindowofTRP601inthis
perinatal stroke rat model, we designed a large protocol
(n¼274 rat pups, two independent experimenters) with
randomized litters in each group (Po0.0001 Kruskal–Wallis;
Figure 2d). When injected 2h post-ischemia at 1mg/kg (i.p.),
TRP601-induced reduction of infarction was around 40%
(% infarction: 11.78±1.01%; n¼47, Po0.001 post hoc Dunn’s;
Figure 2d) and remained signiﬁcant (19.18% reduction) when
TRP601 was added up to 6h post-ischemia (% infarction:
16.01±0.92%; n¼47, Po0.05 post hoc Dunn’s; Figure 2d).
The most clinically relevant administration route being i.v.
injection, we set up similar experiments with post-ischemia
intrajugular bolus of TRP601. Lesion scores on the entire
brain and also section-based infarction quantiﬁcations con-
vergedtoconcludethati.v.injectedTRP601(0.1–1mg/kg;1h
post-ischemia) considerably reduces ischemia-induced brain
lesions along the rostro-caudal axis (Figures 2e and f),
correlatingwithasigniﬁcantneurologicalscoreameliorationin
sensory and motor proﬁling assays (Table 2). We further
investigated if cerebroprotection was long-lasting. At 21 days
post-ischemia, the ipsilateral hemisphere of vehicle-treated
animals exhibited a large cavity in the full thickness of the
frontoparietal cortex (% cavitation: 12.5±3.53%; n¼6) and a
tissue loss (32.33±5.56%), which were markedly reduced in
TRP601-treated rats (% cavitation: 1.42±0.68%; n¼12; %
tissue loss: 12.1±3.9%; Figures 2g and h), correlating with
reduced astrogliosis (Supplementary Figure S3). Hence, in
7-day-old rats subjected to perinatal stroke, TRP601 provided
sustained neuroprotection and neurological improvement,
with a 6h time window for administration.
TRP601 prevents apoptosis, caspase activation and
cytochrome c release in vivo. Both in vivo propidium
iodide staining and ex vivo terminal transferase dUTP nick-
end labeling analysis of ipsilateral regions in brain sections
from ischemic pups revealed a massive TRP601-sensitive
cell death with apoptotic phenotype (Figures 2i and j). When
administered at reperfusion, TRP601 prevents Casp2
processing (Figure 2k) and activation of all caspase-like
activities, whereas TRP901 only reduces the DEVDase
activity (Figures 2k and l). Previous reports had suggested
that Casp2 may act directly and/or through Bid/Bax on
mitochondrial membranes.
43,44 Using the mitochondria
isolated from neonatal brain, we found that a mixture
containing rCasp2 and full-length Bid induce TRP601-
sensitive cytochrome c release, correlating with Casp2-
induced Bid cleavage (Supplementary Figure S4). In
addition, cytochrome c detection at 24h post-ischemia in
the ipsilateral cytosolic versus mitochondrial brain fraction
indicates that TRP601 (added at reperfusion; i.p.) prevents
the mitochondrial release of cytochrome c in vivo
(Figure 2m), correlating with TRP601-mediated prevention
of matrix swelling (Figure 2n).
TRP601 reduces HI brain injury. We next decided to
determine whether the TRP601 pharmacological spectrum of
use might include the most widely used neonatal HI model,
where a focal brain injury occurs in 8-day-old rats after
unilateral carotid ligation and exposure to 7.8 % oxygen for
50min.
45 Indeed, a single dose of TRP601 (1mg/kg; i.p.)
administered just after hypoxia induces a signiﬁcant
reduction of infarct volume (30.3%; P¼0.0239 Student’s
t-test; V¼60.22±8.47mm
3, n¼24 versus control
V¼86.43±6.54mm
3, n¼19), percentage infarction
(48.48±3.13% versus 34.17±4.69%; P¼0.0287 Mann–
Whitney; Figure 3a), and tissue loss (27.5%; P¼0.0412
Mann–Whitney; V¼88.64±11.17mm
3 versus control
V¼122.29±6.84mm
3; Figures 3b–d). An early TRP601-
sensitive, but TRP901-insensitive, VDVADase activity
(12pmol/min per mg) was detected as early as 1h post-HI
in the cortex (Figure 3e). TRP601 also reduced various
aspects of HI-induced white matter injury, including
neuroﬁlament degradation (NF68: 64.24±8.5% versus
controls 87.66±5.32%; P¼0.049 Mann–Whitney)
(Figure 3f), oligodendroglial loss (CNPase: 69.56±8.37%
versus controls 91.29±2.59%; P¼0.0307 Student’s t-test)
(Figure 3g) and hypomyelination (MBP: 87.66±8.8% versus
controls 91.03±2.6%; P¼0.041 Student’s t-test) (Figures 3h
and i).
Pentapeptide caspase inhibitor for neonatal neuroprotection
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Cell Death and DiseaseTRP601 does not modify physiological parameters. It is
established that physiological variables can inﬂuence the
outcomes of ischemic injury.
46 Importantly, when injected in
rat pups, TRP601 (1mg/kg) does not signiﬁcantly alter
physiological parameters, including systemic acid–base
balance (arterial blood pH, partial tension of O2, partial
tension of CO2 and plasma [HCO3
 ]), body weight,
temperature, or heart rate (Table 3). Echography and
transcranial color-coded duplex Doppler sonography
showed that heart function and cerebral perfusion are
unchanged in TRP601-exposed neonates (Table 3). In
addition, telemetry experiments in vigil dogs indicated that
Table 2 Neurological beneﬁt at 48h: effect of TRP601 (i.v., 1mg/kg, 1h post-ischemia) on general behavioral proﬁles
Naı ¨ve (n¼20) Isch.+vehicle (n¼20) Isch.+TRP601 (n¼20) P-values (v
2)( n¼20)
Spontaneous activity 1.8±0.4 0.3±0.6 1.1±0.6 0.026 10
 6
Walking (circle versus straight) 0.3±0.4 1.6±0.6 0.8±0.6 1.092 10
 6
Reaction to pain 1.7±0.6 0.7±0.6 1.2±0.6 95.33 10
 6
Paw withdrawal 1.6±0.6 0.3±0.6 1.2±0.6 0.261 10
 6
Mean lesion volume (mm
3) 0 24.3±2.5 9.2±2.3 NA
Sensorimotorneurologicaldeﬁcitswereassessedinablinded mannerin7-day-oldratpups.Animals weresubjected toischemia–reperfusion (asinFigures2d–f)and
treated with 1mg/kg TRP601 (i.v., 1h post-ischemia). At 48h post-ischemia, pups were tested for the following neurological signs and reﬂexes: (i) spontaneous
activity(spontaneousposturalsignssuchasrightforelimb ﬂexionandthoraxtwistingandexplorationofthe cage);(ii)walking(afterischemia pupswalkincirclerather
than straight); (iii) reaction to pain (the pup escapes after the tail is pinched); (iv) paw withdrawal (pups withdraw paw from adhesive pad). Grading scale of
neurologicalexaminationforeachtestitemwas:2fornormal;1forintermediate;and0forabnormal.Aneurologicalscore(mean±S.E.M.)wasattributedforeachtest
in each experimental condition (d.o.f. stands for degree of freedom in the w
2 statistical test). NA, not applicable
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Figure 3 TRP601 reduces neonatal hypoxia–ischemia-mediated brain damage. The 8-day-old rats were subjected to transient unilateral carotid ligation and exposure to
7.8% oxygen during 50min according to the Rice–Vannucci protocol. Pups were injected intraperitoneally (i.p.) with vehicle (’, n¼19) or 1mg/kg TRP601 (&, n¼24)
immediately after the end of hypoxia. Bars indicate S.E.M. *Po0.05. (a and b) Histograms show % infarction (a) and mean volume tissue loss (b) measured at 72h post-
hypoxia–ischemia (HI) after microtubule-associated protein 2 (MAP2) staining at each anatomical level. (c) Rostro-caudal proﬁles. (d) Representative micrograph for MAP2-
stained sections (bregma  3.14mm). (e) Kinetics of Ac-VDVAD-AMC cleavage in the cortex from HI pups at 1, 8, or 24h in the presence or absence of TRP601 (vehicle:
n¼7; TRP601: n¼8 for each time point; ***Po0.0001 two-way analysis of variance (ANOVA)). (f–i) Immunohistochemistry of subcortical white matter in vehicle- (’,
n¼19)and1mg/kgTRP601-(&, n¼24) treatedpups.Histogramsshow:%NF68loss (f),%CNPaseloss(g), and%myelinbasicprotein (MBP)loss(h)measuredat 72h
post-HI. (i) Representative micrograph for MBP staining in the subcortical white matter. Cx, cortex; WM, white matter. Scale bar¼200mm
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Cell Death and Diseasevital signs, heart rate, and electrocardiogram proﬁle including
QT interval corrected for heart rate were not affected by
TRP601 up to the maximal dose tested (i.e., 3mg/kg, i.v.),
suggesting low potential for fatal tachyarrhythmia. Supra-
pharmacological doses of TRP601 in rats had no impact on
central nervous system functions, including behavior, spatial
activity, coordination, and memory.
To exclude the potential risk that TRP601 might affect the
physiological programmed cell death, which contributes to
normal brain maturation, TUNEL (terminal deoxynucleotidyl
transferase dUTP nick-end labeling) ex vivo studies were
performed,anditwasfoundthatratpupstreatedwithTRP601
at postnatal days 5 and 7 (after birth) showed no signiﬁcant
changes in developmental cell death in the brain (Supple-
mentary Table S2). In addition, histological analysis in
7-day-old rat pups treated with high doses of TRP601 found
no inﬂuence on forebrain, middle brain, and hindbrain
maturation at 21 days of age (data not shown).
TRP601 safety proﬁle in adult and neonates support
further translational steps. The bench to bedside
translation of any drug dedicated to the neonatal population
requires speciﬁc PK/PD considerations together with
combined toxicology evaluation in both adult and neonates.
For these reasons, having veriﬁed that TRP601 has no
hemolytic potency, no effect on bleeding time, no impact on
platelet aggregation, and low toxicities on various cultured
primary cells, we then investigated toxicology in adult
animals, together with dedicated studies in rodent and non-
rodent neonates (see Supplementary Materials and
Methods). In multiple-dose regulatory studies in adult dogs,
no TRP601-related cytotoxic effects were observed following
i.v. administration for 14 days at doses up to 3mg/kg per day.
A good vascular and perivascular local tolerance was found
in rabbit ear. TRP601 was found not to be genotoxic when
evaluated in a battery of in vitro and in vivo assays, and
showed no antigenic response in rat. In 7-day-old rat pups,
single-dose administrations of TRP601 indicated low toxicity
of TRP601 (DL50i.v.¼60mg/kg; DL30i.p.4200mg/kg).
Studies with multiple-dose i.v. injections (once every 3 days
during a 2-week period, starting on postnatal day 1 in
newborn Beagle dogs) showed no adverse effect level at
15mg/kg per injection once every 3 days.
Discussion
Neonatal ischemic brain injury triggers multiple pathways of
oxidant stress, inﬂammation, and excitotoxicity that lead to
massive cellular death in the ischemic territory. Caspase-
dependent programmed cell death importantly contributes to
this fate.
7,9,10,14,15,23,24,32,42 In contrast to previous genera-
tions of aspartyl-ﬂuoromethylketone (D-fmk)-based inhibitors
(e.g., z-VAD-fmk (N-benzyloxycarbonyl-Val-Ala-Asp(Ome)-
ﬂuoromethylketone), boc-D-fmk (Boc-Asp (OMe)-ﬂuoro-
methylketone)),aspartyl-methyloxyphenylketone-basedinhibitors
(e.g., Q-VD-OPh) only target the caspase family, efﬁciently
inhibit (all) caspases, have low in vivo toxicity, and present
enhanced pharmacological properties.
10,16,25,33 Our results
show that pharmacological inhibition of a subfamily of
caspases (Casp2, Casp3) with the pentapeptide-mOPh
derivative, TRP601, reduces cortical and white matter
damage in the neonatal brain after excitotoxicity, arterial
stroke, and HI. In all of these experimental paradigms,
TRP601 also reduces gliosis, an inﬂammatory response to
brain ischemia. It has been demonstrated recently that
caspase-8 and Casp3/7 are involved in regulating microglia
activation.
47 Consequently, beside its direct protective effect
on neurons (as observed in primary cortical cell cultures), it
might be important to investigate whether TRP601 (or the
active metabolite D2Me-TRP601) could also exert cerebro-
protective effects through targeting the microglia.
Table 3 Physiological variables in TRP601-treated rat pups
Parameters Vehicle TRP601
Blood hemodynamics and biochemistry
Blood ﬂow (n¼5, ml/min)
1h 4.2±0.9 3.6±0.4
Resistance index
a (n¼8)
1h (cerebral artery) 0.68±0.01 0.64±0.03
Bleeding time (n¼10)
1h 319±34 395±103
Arterial pH (n¼8)
1h 7.42±0.03 7.42±0.02
PaO2 (n¼8, mmHg)
1h 70.84±6.38 69.82±2.24
PaCO2 (n¼8, mmHg)
1h 37.96±2.64 42.06±2.58
HCO3
  (n¼8, mM)
1h 24.16±0.61 26.30±0.76
Cardiac physiology
Heart rate (n¼8, beat/min)
1h 345±13 344±12
LVEDd (n¼8, mm)
1h 0.293±0.015 0.310±0.015
LVO (n¼8, ml/min)
1h 0.135±0.009 0.157±0.015
Fractional shortening (n¼8, %)
1h 54.39±0.96 49.97±2.11
VTIm (n¼8)
1h 4.05±0.11 3.92±0.29
Core temperature (n¼10, 1C)
1h 36.60±0.28 36.40±0.67
3h 36.39±0.54 36.40±0.67
48h 36.63±0.23 36.80±0.23
Body weight (n¼10, g)
Co. 19.49±1.43 19.18±0.95
1h 19.35±1.72 20.40±1.67
48h 20.96±1.25 20.90±0.67
14 days 69.56±1.60 62.00±2.50
Blood hemodynamics, biochemistry, cardiac physiology, temperature, and
body weight were evaluated before and 1h after TRP601 (1mg/kg) or vehicle
injection. Anterior cerebral arteries were located by transcranial color-coded
duplex sonography to measure peak systolic (Vs) and maximum end-diastolic
(Vd) velocities. Resistive index (RI) was calculated as follows: RI¼((Vs Vd)/
Vs), and corresponds to an index of cerebral perfusion. For cardiac physiology,
the left ventricle (LV) was imaged in short axis view, and diastolic diameter
(LVEDd) was deﬁned as the largest LV area. The fractional shortening was
calculated with the following formula: FS (%)¼((LVEDd LVEDs)/
LVEDd) 100. LVED corresponds to left ventricular end-systolic diameter. A
pulsed-wave Doppler spectrum of aortic outﬂow was recorded from supras-
ternal view to evaluate left ventricular output (LVO). Velocity–time integral (VTI)
of aortic ﬂow, aortic root diameter (CSA), and heart rate (HR) were measured to
calculate LVO as follows: LVO¼CSA VTI HR. A pulsed-wave Doppler
spectrum of mitral inﬂow (VTIm) was recorded from the apical four-chamber
view as an index of diastolic function. Statistical analysis was performed by a
mean comparison using a Scheffe test.
aTranscranial Doppler sonography
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Cell Death and DiseaseOur results indicate that TRP601 and its active metabo-
lite(s) (e.g., D2Me-TRP601) inhibit Casp3 and Casp2 in vitro
and in vivo. We also provide evidences suggesting that
TRP601 interrupts the mitochondrial (intrinsic) pathway of
apoptosis in the immature brain, possibly at the level of Casp-
2-mediated Bid cleavage, and upstream cytochrome c
release.
39 We have recently reported that Casp2
 /  mice
subjected to neonatal HI presented signiﬁcantly lower
cerebral infarction, reduced white matter injury, and reduced
Casp3 activation in the thalamus and hippocampus.
32 Lesion
sizes and Casp3 activation were also found reduced in
Casp2-deﬁcientnewbornmicesubjectedtoexcitotoxicity.
32In
addition, we show here that combined administration of
TRP601 with Casp2 silencing did not show any additive effect
against ibotenate challenge. This suggests that the TRP601-
mediated neuroprotection is at least, in part, Casp2-dependent.
Taken together, our data suggest that the in vivo observed
neuroprotection and Casp3 inhibition by TRP601 are at least,
in part, Casp2-dependent. However, we could not formally
exclude that part of the neuroprotective effect of TRP601
could be related to a direct Casp3 inactivation by TRP601 or
D2Me-TRP601 (this latter being a very powerful Casp3
inhibitor in vitro). As the selective Casp3 inhibitor M826 was
previously found neuroprotective against neonatal HI,
24 one
can suggest that the use of a group-II caspase inhibitor might
be of therapeutic interest to cover different conditions,
developmental stages, or regional mechanisms, where
Casp3/7 and Casp2 are variably expressed and activated
through different pathways.
Irrespective of these mechanistic considerations, TRP601
is a lead candidate for neuroprotective strategy in a variety of
perinatal brain injury conditions. The lack of detectable side
effects following in vivo administration of TRP601 to newborn
rodents and dogs support its further evaluation, possibly
in combination with hypothermia
5 or other candidate treat-
ments.
6,48
Materials and Methods
Animal models. Three different animal models were used: neonatal stroke,
excitotoxicity, and HI. Neonatal stroke (focal brain ischemia with reperfusion in the
7-day-old rat) was carried out according to Renolleau et al.
10,41 For HI, 8-day-old
rats or alternatively 9-day-old mice were subjected to unilateral ligation of the left
carotidartery, followedby hypoxia (7.8% O2 for rats and10% O2 for mice, 361C) for
50min, as described.
32 For drug-induced excitotoxicity, ibotenate was administered
i.c.v. to 5-day-old mice, as described.
32 Details for each animal models are given in
Supplementary Material andMethods. SiRNAswere preparedas a solution in JetSI
according to the manufacturer’s recommendations (PolyPlus-transfection, Illkirch,
France). Final solution contained RNAse free water, 0.08mM DOPE, 0.24%
chloroform/7% EtOH, glucose 12.5%, and 0.04mM JetSI. For intracerebral siRNA
administration, 0.4mg siRNA/mice were administered (volume of injection¼2ml)
24h before ibotenate. SiRNA sequences and primers for PCR were reported
previously.
32
Primary cortical neuron culture and cell death analysis. Primary
cortical neuronsfromE14 Swiss miceembryos (Janvier,Le Genest-St-Isle, France)
were cultured in N5 complete medium up to 6 DIV and subjected to serum
deprivation intheabsenceor presenceof TRP601,or alternatively weretransfected
with siRNAs using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) 24h before
serum withdrawal. To monitor cell death parameters, neurons were
co-stained with Hoechst 33342 (nuclear condensation; Sigma, Saint Louis, MO,
USA), JC-1 (5,50,6,60-tetrachloro-1,10, 3,30-tetraethyl-benzimidazolylcarbocyanine
iodide) (mitochondrial transmembrane potential-sensitive probe), and 7-amino
actinomycin D (plasma membrane permeabilization; Sigma), and then subjected to
ﬂuorescence microscopy (DM IRB; Leica, Rueil-Malmaison, France) and ﬂow
cytometry (FACSCalibur; Becton Dickinson, San Jose, CA, USA) analysis, as
described previously.
39 In cellula caspase activities were detected using FAM-
conjugated peptides (CaspaTag ﬂuorescein Caspase Activity Kits; Q-Biogen, MP
Biomedicals, Illkirch, France), as described.
39
Preparation and use of drug solutions. Synthesis of TRP601/
ORPHA133563 (also known as OPH016) is described in Supplementary
Materials and Methods). Research batches where synthesized in-house
(Dr. Richard Casimir). Additional batches were custom synthesized by MP
Biomedicals or alternatively by NeoMPs (PolyPeptide group, Strasbourg, France).
For regulatory safety studies, TRP601 process development and manufacturing of
GMP batches were subcontracted to NeoMPs (PolyPeptide group). For in vitro
studies TRP601 (C40H48F2N6O11; MW: 826.84), D2Me-TRP601 (C38H44F2N6O11;
MW: 798.79), TRP801 (MW: 771.76), and TRP901 (MW: 799.77) were initially
solubilized in100% DMSO.The ﬁnal concentration of DMSO was r1%.For in vivo
efﬁcacy experiments, TRP601, TRP801, and TRP901 were formulated in 0.9%
NaCl containing 10% DMSO for i.p. administration or 2.4% Tween 20 for i.v.
administration. I.v. administration of TRP601 to 7-day-old rats was carried out
intrajugularly using 27-gauge needles. All stock solutions and formulations were
veriﬁed using RP-HPLC. TRP601 has a high degree of lipophilicity (partition
coefﬁcient, LogPoctanol/water¼3.89) and exhibits one pKa of 1.1 (assigned to the
quinoleine group), strongly suggesting that it remains neutral in the plasma.
Bioanalysis of TRP601 in ﬂuids and organ homogenates was conducted by LC/MS/
MS analysis with a precision of 1.00ng/ml in the plasma and 3.00ng/g in
exsanguined brain homogenates (ADME Bioanalyses, Vergeze, France).
Molecular modeling. Starting from the crystal structure of the caspase-2-
inhibitor (Ac–LDESD–CHO) complex (1PYO), pentapeptide inhibitors (including
Ac–VDVAD–CHO and TRP601) were studied in an uncharged form and at a
dielectric constant of 1, using either Insight II or Discovery Studio 2.0 softwares
(Accelrys, San Diego, CA, USA). See details in Supplementary Materials and
Methods.
In vitro enzymatic assays. Kinetics were performed according to the
continuous method. Assays of chromogenic substrate cleavage contained in 100ml
caspase buffer (20mM HEPES, pH 7.4, 0.1% CHAPS, 5mM DTT, 2mM EDTA),
117ng of human active recombinant caspase-2 (Biomol, Plymouth, PA, USA) or
20ng of human active recombinant caspase-3 (Sigma; no. C5974), and 100mM of
chromogenic substrate (Ac–DEVD–para-nitroaniline (pNA) for Casp3 and
Ac–VDVAD–pNA for Casp2) in the presence of a range of concentrations of
inhibitors. For Casp2 assays, the buffer was supplemented with 1M succinate
(kosmotrope agent). Cleavage of the chromogenic substrate as a function of time
wasmonitoredat405nm,andtheinitialvelocity(V0)wasdeterminedfromthelinear
portion of the progress curve. The formation of pNA was followed every 30s for
150min at 371C with a microtiter plate reader (Paradigm Multi-Mode Microplate
Detection Platform, SoftMax Pro 5.2 software; Molecular Devices, St. Gre ´goire
Ce ´dex, France). V0, relative velocities, Km, and IC50 were determined from
experimental data using the GraphPad Prism 5.01 software program. Standard
deviations of the reported values were below 10%. Inhibitor binding afﬁnity
(dissociation constant, Ki) and ﬁrst-order rate constant (k3) parameters were
estimated using R (http://www.R-project.org) to ﬁt the following equation from
Wu and Fritz
49:
½P t ¼½ E 0
½S K i
½I Ks
  
ks
k3
  
1   e k3t= 1þðKi=½I Þð1þ½S =K sÞ ðÞ
hi
Other in vitro assays for calpains, cathepsins, and granzyme activities were
performed as described.
33
Ex vivo biochemistry. Brains of rat or mice pups were removed just after
decapitation. Contralateral and ipsilateral hemispheres were frozen immediately
and kept at  801C. Alternatively, the ipsilateral hemisphere was rapidly micro-
dissected (at 41C) to mainly select the lesioned area (i.e., the estimated penumbra
zone for the neonatal stroke model). Brain samples processing and related
biochemical analyses are described in Supplementary Material and Methods.
Physiological parameters. Blood gas analyses and hemodynamic
evaluations conducted in newborn rats are described in Supplementary Materials
and Methods.
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Cell Death and DiseaseSafety pharmacology and toxicology. Safety experiments conducted in
newborn dogs and rats are described in Supplementary Materials and Methods.
Statistics. Statistical analyses were conducted with Prism 4.0. Data are
presentedasmean±S.E.M.andwereﬁrstanalyzedwithaKSnormalitytest.When
thedatapassedthenormalitytest,theappropriateparametrictesthasbeenapplied
(Student’s t-test or ANOVA), followed by the suitable post hoc test if necessary
(Bonferronitest).Whenthedatadidnotpassthenormalitytest,theappropriatenon-
parametric test has been applied (Mann–Whitney or Kruskal–Wallis tests), followed
by the suitable post hoc test if necessary (Dunn’s test). Neurological scores were
statistically analyzed with a w
2. Statistical signiﬁcance is indicated by a single
asterisk (Po0.05), and two or three asterisks (Po0.01 or o0.001, respectively).
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